AstraZeneca struck a licensing transaction with Sino Biopharmaceutical for ex-China rights to a late-phase COPD challenger targeting chronic obstructive pulmonary disease, stepping up its respiratory pipeline development. AstraZeneca will pay Sino Biopharmaceutical $200 million upfront to obtain ex-China rights tied to the late-stage asset. The transaction is positioned as a direct commercial expansion lever for AstraZeneca, transferring geography-specific rights that could accelerate development and reduce duplication of regional execution. Market attention will focus on how the acquired late-phase program fits AstraZeneca’s existing COPD strategy and whether it supports a broader respiratory differentiation plan. For Sino Biopharmaceutical, the deal provides near-term capital while continuing to manage its remaining respiratory and pipeline priorities outside the licensed geography.